These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28228973)

  • 1. Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy.
    Larkindale J; Abresch R; Aviles E; Bronson A; Chin J; Furlong P; Gordish-Dressman H; Habeeb-Louks E; Henricson E; Kroger H; Lynn C; Lynn S; Martin D; Nuckolls G; Rooney W; Romero K; Sweeney L; Vandenborne K; Walter G; Wolff J; Wong B; McDonald CM; Duchenne Regulatory Science Consortium Imaging-Dmd Consortium And The Cinrg Investigators MO
    PLoS Curr; 2017 Jan; 9():. PubMed ID: 28228973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
    Conrado DJ; Larkindale J; Berg A; Hill M; Burton J; Abrams KR; Abresch RT; Bronson A; Chapman D; Crowther M; Duong T; Gordish-Dressman H; Harnisch L; Henricson E; Kim S; McDonald CM; Schmidt S; Vong C; Wang X; Wong BL; Yong F; Romero K;
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):441-455. PubMed ID: 31127458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy.
    Lingineni K; Aggarwal V; Morales JF; Conrado DJ; Corey D; Vong C; Burton J; Larkindale J; Romero K; Schmidt S; Kim S;
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):318-332. PubMed ID: 34877803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.
    Servais L; Camino E; Clement A; McDonald CM; Lukawy J; Lowes LP; Eggenspieler D; Cerreta F; Strijbos P
    Digit Biomark; 2021; 5(2):183-190. PubMed ID: 34723071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular Dystrophy, April 20-21, 2017, Bethesda, Maryland, USA.
    Franson T; Kinnett K; Cripe TP
    Ther Innov Regul Sci; 2019 Jan; 53(1):154-163. PubMed ID: 29714576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
    Thongsing A; Likasitwattanakul S; Sanmaneechai O
    Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe.
    Aartsma-Rus A; Goemans N
    Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.
    Rudick RA; Larocca N; Hudson LD;
    Mult Scler; 2014 Jan; 20(1):12-7. PubMed ID: 24057430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials.
    Haberkamp M; Moseley J; Athanasiou D; de Andres-Trelles F; Elferink A; Rosa MM; Magrelli A
    Neuromuscul Disord; 2019 Jul; 29(7):514-516. PubMed ID: 31272741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body clearing, staining and screening of calcium deposits in the mdx mouse model of Duchenne muscular dystrophy.
    Bozycki L; Łukasiewicz K; Matryba P; Pikula S
    Skelet Muscle; 2018 Jul; 8(1):21. PubMed ID: 30025544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy.
    Al-Zaidy SA; Lloyd-Puryear M; Kennedy A; Lopez V; Mendell JR
    Int J Neonatal Screen; 2017 Jun; 3(2):8. PubMed ID: 31588416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duchenne muscular dystrophy drugs face tough path to approval.
    Hodgkinson L; Sorbera L; Graul AI
    Drugs Today (Barc); 2016 Mar; 52(3):199-202. PubMed ID: 27186594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.
    Landfeldt E; Alfredsson L; Straub V; Lochmüller H; Bushby K; Lindgren P
    Pharmacoeconomics; 2017 Feb; 35(2):249-258. PubMed ID: 27798808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.
    Peay HL; Hollin I; Fischer R; Bridges JF
    Clin Ther; 2014 May; 36(5):624-37. PubMed ID: 24852596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.
    Bushby K; Connor E
    Clin Investig (Lond); 2011 Sep; 1(9):1217-1235. PubMed ID: 22639722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary.
    Finder J; Mayer OH; Sheehan D; Sawnani H; Abresch RT; Benditt J; Birnkrant DJ; Duong T; Henricson E; Kinnett K; McDonald CM; Connolly AM
    Am J Respir Crit Care Med; 2017 Aug; 196(4):512-519. PubMed ID: 28636407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
    Gatheridge MA; Kwon JM; Mendell JM; Scheuerbrandt G; Moat SJ; Eyskens F; Rockman-Greenberg C; Drousiotou A; Griggs RC
    JAMA Neurol; 2016 Jan; 73(1):111-6. PubMed ID: 26594870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.